電子スピン共鳴(Electron Spin Resonance; ESR)法による生物医学応用―医薬品開発のための抗酸化能評価―

  • 李 昌一
    神奈川歯科大学生体管理医学講座薬理学分野・ESR研究室

書誌事項

タイトル別名
  • Biomedical Application of Electron Spin Resonance (ESR) Spectroscopy-Assessment of Antioxidant Property for Development of Drugs-
  • 電子スピン共鳴(Electron Spin Resonance; BSR)法による生物医学応用--医薬品開発のための抗酸化能評価
  • デンシ スピン キョウメイ Electron Spin Resonance BSR ホウ ニ ヨル セイブツ イガク オウヨウ イヤクヒン カイハツ ノ タメノ コウサンカノウ ヒョウカ

この論文をさがす

抄録

  Reactive oxygen species (ROS) are associated with oxidative stress-mediated alterations under pathophysiological conditions, and particularly brain ischemia, brain tumor, and neurodegenerative diseases. Electron spin resonance (ESR) is recognized as one of the most powerful techniques available for the detection of ROS in tissues and cells. We previously developed an in vitro ESR-based technique for the detection of free radical reactions in biological systems. In addition, significant advances in the field of in vivo ESR techniques over recent years have now made it possible to visualize the distribution and metabolism of oxidative stress, and the degree of tissue oxygenation in vivo. Nitroxyl radicals are very useful as exogenous spin probes for measuring free radical distribution, oxygen concentration, and redox metabolism by in vivo ESR in biological systems, using a combination of these ESR methods collectively focused on animal models of disease such as spontaneously hypertensive rat (SHR) or stroke-prone SHR (SHRSP) for the assessment of antioxidant property of drugs. Our results suggest that ESR could be applied to the assessment of antioxidant property on oxidative stress in target organs, especially brain, using animal disease models, SHR or SHRSP. After screening drugs for antioxidant property using such as in vitro or in vivo ESR assessment, we'll be able to develop and find novel antioxidant drugs for ROS-induced brain disease in the near future.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 128 (5), 753-763, 2008

    公益社団法人 日本薬学会

被引用文献 (2)*注記

もっと見る

参考文献 (72)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ